Le Lézard
Classified in: Health
Subject: ANW

SOUTH DAKOTA VACCINE INNOVATOR USING USDA-APPROVED PLATFORM TECHNOLOGY TO DEVELOP URGENTLY NEEDED VACCINE OPTIONS FOR POULTRY INDUSTRY


Company to leverage platform technology approved by the USDA for influenza vaccines in swine and cattle to create new solutions if vaccine use for avian influenza is approved

BROOKINGS, S.D., April 24, 2023 /PRNewswire/ -- Medgene, a South Dakota-based animal health company, will be conducting a study to test a vaccine produced by its USDA-approved platform technology against a variant of avian influenza.

Highly Pathogenic Avian Influenza (HPAI, or bird flu) has become widespread among wild birds and created significant economic loss to the U.S. poultry industry. The H5N1 HPAI variant is being described as the largest bird pandemic recorded, resulting in the destruction of millions of commercially raised geese, turkeys and chickens, as well as killing untold numbers of wild birds.  While the total economic impact of HPAI is difficult to measure, the need for potential solutions is urgent.

Dr. Alan Young, Chief Technology Officer for Medgene, will be leading the study using the company's platform technology that has been approved by the USDA for swine and cattle vaccines and an influenza variant that is known to cause disease in both the swine and turkey industries.  "People are often surprised that a vaccine technology can work across species.  The reality is that diseases have much in common from animal to animal, including transmission.  Our platform technology allows our influenza vaccine for swine to be adopted to address influenza in turkeys as well as the H5N1 variant in all birds."

Another feature of Medgene's platform technology is the speed in which specific vaccines can be created to address the multiple variants of H5N1, whereas traditional vaccines can take years to develop, test, and achieve regulatory approval. 

The study is expected to begin in May with results in approximately six weeks from the start date.  Young added, "We're expecting to see strong evidence for immunity against avian influenza.  Once we observe the desired response, we'll be able to make a HPAI vaccine option available if the USDA determines that vaccination is an appropriate option for some or all sub-species of poultry, such as turkeys or pheasants which add millions of dollars to the economies of states like South Dakota.  Additionally, our platform technology permits differentiation of infected and vaccinated animals."

Medgene has previous experience in providing vaccines under emergency conditions.  In 2021, the company was issued Emergency Use Authorization to produce and distribute the only vaccine against Rabbit Hemorrhagic Disease (RHDV2) approved in the United States.

SOURCE Medgene


These press releases may also interest you

at 07:30
Abbott today announced financial results for the first quarter ended March 31,...

at 07:25
Alterity Therapeutics ("Alterity" or...

at 07:10
QuidelOrtho Corporation (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial...

at 07:05
Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company's SPRINT (SARS-Cov-2 PRotease INhibitor Treatment)...

at 07:05
The federal government has taken an important step on the Canada Disability Benefit by launching the program in the 2024 budget, however, the funding allocation and roll-out details are inadequate in providing the support people living with...

at 07:05
Allegheny Health Network's (AHN) Allegheny General Hospital (AGH) was the top U.S. enrollment site for a landmark international clinical trial comparing the performance and durability of self-expanding and balloon-expandable transcatheter aortic...



News published on and distributed by: